RxDoctor Payments Data

Byron Tatsch, NP

Gerontology · Spokane Valley, WANPI 1649932948

Payments from drug & device makers

What this record shows

14 manufacturers reported payments, led by Boston Scientific at 39.2% of the total. 2025 is the largest year on record at $2,815, more than ten times the $88 reported in 2022. Among gerontology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,359in general payments, 2019–2025

Across 61 payments — averaging $71.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Si-bone, Inc.$976
  • Saluda Medical Americas, Inc.$968
  • Nevro Corp.$251
  • Collegium Pharmaceutical, Inc.$186
  • Globus Medical$58
  • plus $210 from 8 others

What the payments were for

  • Travel & lodging$2,37154%
  • Food & beverage$1,98846%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,359 in reported general payments places this provider in the 95th percentile of 105 gerontology providers in Washington.

See all gerontology providers in Washington

Medicare billing

Part B allowed, 2024
$95,153
Medicare patients
130
Services billed
873

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl109$65,355
Nucynta ErTapentadol Hcl43$63,156
Buprenorphine203$43,417
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,289$34,181
Xtampza ErOxycodone Myristate33$27,652
Fentanyl137$14,699
ButransBuprenorphine40$12,211
Butorphanol Tartrate34$7,740
Tramadol Hcl ErTramadol Hcl60$7,603
Pregabalin221$6,916
OxycontinOxycodone Hcl13$5,621
MovantikNaloxegol Oxalate12$5,095
Gabapentin164$4,486
Morphine Sulfate ErMorphine Sulfate158$4,115
Oxycodone Hcl280$4,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er, Xtampza Er$186$156,164185 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 gerontology providers in Washington.

Other gerontology in Spokane Valley

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →